

Environment

Environment

Environmental management

Environmental issues such as climate change are serious global problems that threaten the health and wellbeing of people worldwide. Our environmental initiatives through our business activities will contribute to solving these issues, and by evaluating and appropriately responding to the impact of risks and opportunities on our business, we will contribute to achieving a sustainable society, which will lead to the sustained enhancement of corporate value.

Under our Basic Environmental Policies, Sumitomo Dainippon Pharma formulates medium- to long-term

environmental goals and medium-term environmental plans and annual implementation plans. Meanwhile, we evaluate such initiatives at the Environmental and Safety Committee. In fiscal 2020, the Environmental and Safety Committee and Management Committee discussed the stance we ought to take as a company, and the Board of Directors in May 2021 decided to revise the Basic Environmental Policies. This revision clarifies the proactive disclosure of environmental information, the promotion of dialogue with stakeholders, and our stance undertaking initiatives over our entire value chain.

Results and explanation of Mid-term Environmental Goals (fiscal 2020 goals)
✔ Achieved
 ⚠ Not achieved by slight margin
 ✘ Not achieved

Priority issues	Objectives	Results	Explanation
Building a low-carbon society	Climate change measures 1. Reduce CO ₂ emissions by 23% from FY2005 level by FY2020 2. Improve per-unit CO ₂ emissions by 1% or more per year Energy Saving Measures 3. Improve per-unit energy consumption by 1% or more per year	1. ✔ 2. ✔ 3. ✔	1. 34% reduction from FY2005 level Reason: Contribution of reorganization into two plants at the end of March 2019, in addition to capital investment in energy conservation and CO ₂ reductions (including upgrading to high efficiency equipment and installation of LED lighting) and measures to conserve energy and save electricity in summer and winter. 2. 1.4 % improvement on previous fiscal year 3. 1.4% improvement on previous fiscal year Reason: Contribution of improvements in energy efficiency and associated improvement in per-unit CO ₂ emissions
Establishment of a sound material-cycle society	1. Maintain final landfill disposal at less than 1% of waste generated 2. Reduce waste generated by about 25% from FY2010 level in FY2020 3. Maintain the recycling rate to 80% or more	1. ✔ 2. ✘ 3. ⚠	1. Final disposal rate: 0.7% Reason: Proactive renewal to non-landfill disposal outsourcing contracts 2. Decreased by 14% from FY2010 level Reason: Greater than expected increase in production compared to that envisaged at time of goal setting 3. Recycling rate: 79.8% (however both FY2018 and FY2019 achieved the goal with 83%) Reason: Reduction in generation amount of waste oil with a high recycling rate in FY2020, mainly due to decrease in production volume of active pharmaceutical ingredients (APIs) for MEROPEN®
Biodiversity conservation	Effective Use of Water Resources Reduce water consumption by about 20% from FY2010 level in FY2020	✔	Reduced by 35% from FY2010 level Reason: Contribution of reorganization into two plants at the end of March 2019, in addition to changing the number of times certain facilities were washed with water.
Chemical substances management	Maintain atmospheric release rate at less than 1% of the volume of Pollutant Release and Transfer Register (PRTR) substances and volatile organic compounds (VOC) substances handled	✔	PRTR substances handled: 0.3% VOC substances handled: 0.7% Reason: Reduced atmospheric release due to installation of equipment to recover toxic chemical substances
Environmental communications	1. Promote communication with stakeholders 2. Promote communication with Group Companies 3. Enhance environmental education	1. ✔ 2. ✔ 3. ✔	1. Obtained third party assurance to enhance the reliability of disclosed information; obtained A- rating for climate change and B rating for water security from the Carbon Disclosure Project (CDP; FY2020); held ESG meetings 2. Implemented EHS inspections, held meetings for exchange of environmental safety information between domestic Group companies 3. Held training for new employees and e-learning for all employees during Environment Month

Revision of Basic Environmental Policies

The decision to revise our Basic Environmental Policies was made in the Board of Directors meeting held on 12 May 2021. For further details, please see:

<https://www.ds-pharma.com/csr/environment/policy.html>

Mid- to long-term environmental goals

We have set the following mid- to long-term environmental goals to achieve a sustainable society.

Long-term environmental goals (targeting fiscal 2030 and fiscal 2050)

- Reduce our greenhouse gas (GHG) emissions (scopes 1 and 2) by 35% from fiscal 2017 level by fiscal 2030, and aim to achieve net-zero emissions by fiscal 2050.
- Reduce water withdrawal by 12% from fiscal 2018 level by fiscal 2030.
- Maintain recycling rate at 80% or higher and aim for at least 85% by fiscal 2030.
- Maintain final disposal rate at less than 1% and aim for less than 0.5% by fiscal 2030.

Mid-term Environmental Goals

Please see our website for our Mid-term Environmental Goals (fiscal 2021 – fiscal 2023).

<https://www.ds-pharma.com/csr/environment/burden.html>


The results of our fiscal 2020 Mid-term Environmental Goals are outlined in the table on page 59.

Building a low-carbon society

We have agreed with the Science Based Targets initiative (SBTi) that promotes the setting of GHG reduction targets in alignment with the Paris Agreement, and have formulated our GHG reduction targets for up to fiscal 2030 aligned with the well-below 2°C (WB-2°C) level set in the SBTi. Each year, we take applications from worksites for capital investment in energy conservation and CO₂ emission reductions and have been systematically introducing LED lighting and more energy-efficient equipment based on considerations such as the cost effectiveness (yen/t-CO₂) of CO₂ emission reductions and investment payback periods.

In August 2021, we also replaced most of the city gas used in cogeneration systems and others at the Suzuka Plant with carbon-neutral city gas supplied by Toho Gas Co., Ltd. (volume: 5,000 thousand m³/year, period: 2 years, 8 months) in order to contribute to reducing global GHG emissions and promote various environmental conservation projects around the world.

CO₂ emission trends




The fiscal 2019 figures for Scope 1 and Total of Scope 1 and Scope 2 have been changed to improve accuracy.

Sumitomo Dainippon Pharma supports Japan's Carbon Neutral Declaration and aims to reduce GHG emissions to net-zero (Scope 1 + 2) by fiscal 2050 by proactively adopting energy-saving and emissions-reducing technologies, which are expected to advance in the future, as well as renewable energy, the use of which is expected to become widespread, to achieve decarbonization.

We are also working to calculate greenhouse gas emissions across the supply chain and plan to implement initiatives to reduce GHG emissions across our value chain going forward.

Fiscal 2020 CO₂ emissions by scope



KPIs

• Implementation of measures to achieve FY2030 and FY2050 goals

To achieve the long-term goals, we will consider and implement specific measures, such as continuous investment in equipment to reduce CO₂ emissions as well as promoting a switch to renewable energy.

• Per-unit energy consumption

To achieve more efficient use of energy, we will verify improvements in per-unit energy consumption.

Environment


Effective use of resources (water and waste)

Effective use of water resources

Ensuring the quality and sufficient amount of fresh water is essential for our manufacturing and other business activities. We are working to reduce water withdrawal with an aim of utilizing water resources effectively and reducing environmental impact.

We have already taken measures, which include reviewing washing frequency at some production facilities and installing water-saving nozzles on faucets for washing in animal breeding facilities. We will continue to make water use more efficient and take measures to save water to reduce water withdrawal.

Water withdrawal by source



As some of the tap water and other water withdrawal at one facility had not been counted, the amounts of tap water and other water withdrawal for FY2010 and FY2016 - 2018 have been adjusted retroactively. As a result, the amounts differ from the amounts stated in previous Integrated Reports.

KPIs

- **Implementation of measures to achieve FY2030 goals**
To achieve the goal for fiscal 2030, which is the reduction of water withdrawal, we will implement concrete measures, including expanding existing measures to other sites and considering and selecting new measures to reduce water withdrawal.

Reduction of waste


To make effective use of limited resources, Sumitomo Dainippon Pharma strives to actively practice the "3Rs" of waste management (reduce, reuse, recycle).

Going forward, we will continue to promote recycling through the active pursuit of thorough waste separation and consignment of recyclable waste to waste recyclers.

In addition, marine plastic waste has been recognized

as a new environmental problem in recent years. As part of our efforts to eliminate plastic bottles, we are promoting their replacement with environmentally friendly containers and products, including metal bottles and canned beverages, in the vending machines we install and manage at our business facilities. Furthermore, to encourage recycling of waste plastic, we plan to formulate goals that will contribute to recycling of plastic resources.

Waste-related indicators



* Figures in parentheses show the volume of specially-controlled industrial waste generated out of the volume of waste generated

KPIs

- **Recycling rate and final disposal rate of waste**
We will verify the recycling rate and final disposal rate of waste as an indicator to measure the progress of efforts to promote recycling and avoid final disposal of waste as much as possible.

Proper information disclosure and response to TCFD

Identifying risks and opportunities

In order to support the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD), we are working to analyze, evaluate, conduct concrete initiatives and disclose information concerning climate change and water related risks and opportunities according to the recommendations, under our risk management system. With regard to water risk in particular, we have implemented surveys of risks related to current and future water supply and demand at our main business sites and vulnerabilities of downstream environments. In fiscal 2020, we surveyed water related issues that have actually arisen in the past and future region-specific issues.

In future, we will comprehensively analyze and evaluate these results. Moreover, with regard to managing

supply chain risks, we continue to evaluate water risks, firstly of raw material manufacturers and manufacturing contractors for our key products, using a water risk atlas, Aquaduct, published by the World Resources Institute.

Third-party assurance

Fiscal 2020 environmental information indicated with a  in the Integrated Report 2021 has received third-party assurance from KPMG AZSA Sustainability Co., Ltd. in order to enhance the reliability of the information. The Independent Assurance Report is on page 63.

KPIs


• Promotion of evaluation of risks and opportunities related to climate change and water

We will aim for sustained enhancement of corporate value by assessing financial impact and considering the incorporation of the results into management strategy based on the TCFD recommendations.

• Acquisition of third-party assurance for environmental data

We will continue to obtain third party assurance to improve the reliability of environmental data.

Overview of environmental impact (FY2020)



Boundary of calculation: Sumitomo Dainippon Pharma Co., Ltd. facilities in Japan only (plants, research laboratories, distribution centers, Osaka Head Office, Tokyo Head Office, branches and business offices). Water withdrawal, total amount of water discharged, and waste excludes branches and business offices.

Methods of Calculation and Emissions Intensity, etc.

*1 (Purchased electricity × unit calorific value + purchased heat × unit calorific value + fuel consumption × unit calorific value) × 0.0258 kI/GJ
The unit calorific values and the types of fuel to be calculated are based on "Act on the Rational Use of Energy."

*2 Fuel consumption × fuel unit calorific value × fuel CO₂ emissions factor
The unit calorific values and CO₂ emissions factors are based on "Greenhouse Gas Emissions Accounting, Reporting, and Disclosure System" which is provided in "Act on Promotion of Global Warming Countermeasures."

*3 Purchased electricity × electricity CO₂ emissions factor#1 + purchased heat × heat CO₂ emissions factor#2
(Note) #1 The value (0.33 t-CO₂ / thousand kWh) which The Federation of Pharmaceutical Manufacturers' Associations of JAPAN has adopted to manage the progress of its CO₂ reduction target
#2 The values based on "Greenhouse Gas Emissions Accounting, Reporting, and Disclosure System" which is provided in "Act on Promotion of Global Warming Countermeasures." However, we use values provided by Sumitomo Chemical Co, Ltd. for sites located on the premises of Sumitomo Chemical Co., Ltd.

*4 The amount of water withdrawal from tap water, industrial water, ground water, and other.

*5 Total amount of water discharged into sewerage and public water bodies and so on. As the amount of water discharged is not measured at each facility, the total amount of water discharged is considered to be equivalent to the total amount of water withdrawal.



Independent Assurance Report

To the President and CEO of Sumitomo Dainippon Pharma Co., Ltd.

We were engaged by Sumitomo Dainippon Pharma Co., Ltd. (the “Company”) to undertake a limited assurance engagement of the environmental performance indicators marked with  (the “Indicators”) for the period from April 1, 2020 to March 31, 2021 included in its Integrated Report 2021 (the “Report”) for the fiscal year ended March 31, 2021.

The Company’s Responsibility

The Company is responsible for the preparation of the Indicators in accordance with its own reporting criteria (the “Company’s reporting criteria”), as described in the Report.

Our Responsibility

Our responsibility is to express a limited assurance conclusion on the Indicators based on the procedures we have performed. We conducted our engagement in accordance with the ‘International Standard on Assurance Engagements (ISAE) 3000, Assurance Engagements other than Audits or Reviews of Historical Financial Information’ and the ‘ISAE 3410, Assurance Engagements on Greenhouse Gas Statements’ issued by the International Auditing and Assurance Standards Board. The limited assurance engagement consisted of making inquiries, primarily of persons responsible for the preparation of information presented in the Report, and applying analytical and other procedures, and the procedures performed vary in nature from, and are less in extent than for, a reasonable assurance engagement. The level of assurance provided is thus not as high as that provided by a reasonable assurance engagement. Our assurance procedures included:

- Interviewing the Company’s responsible personnel to obtain an understanding of its policy for preparing the Report and reviewing the Company’s reporting criteria.
- Inquiring about the design of the systems and methods used to collect and process the Indicators.
- Performing analytical procedures on the Indicators.
- Examining, on a test basis, evidence supporting the generation, aggregation and reporting of the Indicators in conformity with the Company’s reporting criteria, and recalculating the Indicators.
- Making inquiries and reviewing materials including documented evidence of one of the laboratories of the Company selected on the basis of a risk analysis, as alternative procedures to a site visit.
- Evaluating the overall presentation of the Indicators.

Conclusion

Based on the procedures performed, as described above, nothing has come to our attention that causes us to believe that the Indicators in the Report are not prepared, in all material respects, in accordance with the Company’s reporting criteria as described in the Report.

Our Independence and Quality Control

We have complied with the Code of Ethics for Professional Accountants issued by the International Ethics Standards Board for Accountants, which includes independence and other requirements founded on fundamental principles of integrity, objectivity, professional competence and due care, confidentiality and professional behavior. In accordance with International Standard on Quality Control 1, we maintain a comprehensive system of quality control including documented policies and procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

KPMG AZSA Sustainability Co., Ltd.
Osaka, Japan
October 18, 2021

Contribution to Societies

Contribution to societies

Material issues Sumitomo Dainippon Pharma has set targets and KPIs, and we have provided a list of them on pages 25–26.

Contribution to global health

Material issues

Development of drugs to treat malaria and antimicrobial-resistant (AMR) bacterial infections

Expectations of pharmaceutical companies are rising amid the COVID-19 pandemic and other pressing issues around international healthcare sustainability.

Sumitomo Dainippon Pharma is working to solve issues through research in the area of infectious diseases which pose an international threat such as malaria and antimicrobial-resistant (AMR) bacterial infections. We believe that these efforts will not only contribute to the achievement of the SDGs, but will also increase our presence as a global pharmaceutical company.

In a major initiative, the preclinical development project for a new pre-erythrocytic malaria vaccine, a three-way collaboration between Ehime University, Sumitomo Dainippon Pharma, and PATH of the United States, was selected for a grant by the Global Health Innovative Technology Fund (the GHIT Fund) in March 2021. It is the third consecutive year that our projects have been selected following the GHIT Fund grants for joint research into an asexual blood-stage vaccine and a transmission-blocking vaccine being implemented by Ehime University and Sumitomo Dainippon Pharma. Successful completion of the project will advance development toward achievement of a comprehensive malaria infection, onset, and transmission-blocking vaccine. We have also been making recommendations for improvement of the research and policy environment to accelerate vaccine development and supply through dialogue with the League of Legislators to Eliminate Malaria by 2030, which was established in March 2021.

Strengthening of public-private collaboration on countermeasures against AMR and appropriate use of antibiotics

Since June 2019, we had been working with 31 doctors and pharmacists at ten hospitals in Vietnam to implement drug susceptibility surveillance research aimed at the appropriate use of antibiotics and countermeasures to antimicrobial resistance (AMR). Analysis of the research data was completed in August 2020, and we are providing a detailed report and exchanging opinions with each hospital with the aim of further spreading awareness about the importance of using drug susceptibility data in routine testing as information for making decisions to select the best antibiotics for treatment in each medical institution.

Promotion of public awareness-raising activities for health, hygiene, and nutrition

Sumitomo Dainippon Pharma provides an NPO-led health improvement program for mothers and children in Cambodia’s Kampong Cham Province. In fiscal 2020, the program displayed awareness-raising posters and pamphlets on integrated management of childhood diseases, child nutrition and hygiene, including COVID-19 prevention measures, in local hospitals, health centers, markets and municipal buildings, and distributed them through health district offices and health centers, mainly to expectant mothers and mothers with children under five years old.

KPIs

- **Progress of development in infectious diseases area**
—Number of projects
—Number of products (number of products launched)
 The number of projects and number of products (number of products launched) will be used as indicators to measure the progress of development and the Company’s contribution in the infectious diseases area.
- **Number of policy recommendations in infectious diseases area**
 The number of policy recommendations will be set as an indicator to make further improvements in the environment in the infectious diseases area, which will promote research and development in the area.
- **Number of doctors and pharmacists who participated in the AMR countermeasure support program**
 The number of participants in support programs to help healthcare professionals will be used as an indicator in efforts to further promote public awareness.
- **Number of local residents assisted by maternal and child health programs in developing countries**
 We will promote public awareness around health, hygiene, and nutrition by providing assistance to more local residents through our programs.

Initiatives to improve access to medicines

Material issues

Even with today’s advances in medicine, there are still many unmet medical needs, and an R&D-oriented pharmaceutical company has a mission to solve this issue. In addition, there are parts of the world where it is difficult for all people to receive equal access to necessary healthcare due to inadequate medical systems and poverty.

In addition to research and development of products,

Contribution to Societies

Sumitomo Dainippon Pharma works to solve issues related to healthcare access by raising public awareness of health, hygiene, and nutrition in collaboration with international organizations, government agencies, research institutions, and civil society.

As part of these efforts, since 2017 Sumitomo Dainippon Pharma has been participating in the Access Accelerated partnership initiative by organizations around the world, including global pharmaceutical companies, City Cancer Challenge, and PATH. Together with governments and local NGOs in the focus countries (Kenya, Ghana, and Vietnam), we are working for public education and pharmaceutical deregulation in disease areas with high local needs (non-communicable diseases such as cancer, heart disease, and diabetes) aiming for improvements in access to pharmaceuticals, even during the COVID-19 pandemic.

Promotion of public awareness-raising activities with the aim of improving medicine-related literacy

Using pharmaceuticals with a proper appreciation and understanding of treatment methods and adverse reactions is very important in improving access to medicines. We provide “Kusuri-no-shiori,” “Instructional Leaflets,” and guidance for patients using our pharmaceuticals and their families to promote appropriate use.

Response to requests for the development of unapproved and off-label drugs

As an initiative to provide new treatment options in areas with high unmet medical needs, Sumitomo Dainippon Pharma also addresses to requests for development of

unapproved and off-label drugs. Thus far, we have obtained four such approvals, including a conditioning treatment prior to autologous hematopoietic stem cell transplantation for malignant lymphoma in March 2020.

Improvement of healthcare infrastructure in developing countries

Material issues

Support for capacity building of healthcare professionals, development of healthcare networks, etc.

From July 2016, we have worked with NPOs, local governments, and the community to provide a health improvement program for mothers and children in Cambodia’s Kampong Cham Province. To date, we have trained 57 Community Care volunteers for Mothers and Newborns, who visited the homes of 467 antenatal women and 470 postnatal women in fiscal 2020.

Moreover, in collaboration with the local government, we donated surgical masks and disinfectant solutions to 12 health centers in the province through an NPO with the aim of ensuring the safe operation of the centers, which are the bases for local healthcare.



Home visit by a Community Care volunteers for Mothers and Newborns (Cambodia)

KPIs

- **Number of programs aiming to improve medicine-related literacy**

The number of programs implemented will be used as an indicator due to the importance of providing opportunities for people to correctly learn about treatment using medicines and their side effects.

- **Number of responses to requests for unapproved and off-label drugs**

The number of responses on unapproved and off-label drugs will be used as an indicator to measure our contribution to new treatment options.

- **Number of policy recommendations by the Company on access to medicines**

We will also take part in policy recommendations aimed at provision of fairly-priced drugs, leading to regulatory development.

KPIs

- **Number of community care volunteers trained through maternal and child health programs in developing countries**

- **Number of partnerships working to improve healthcare infrastructure in developing countries**

We will contribute to improving infrastructure in developing countries by setting the number of specialist human resources trained and the number of partnerships as indicators because securing human resources in healthcare and pharmaceutical deregulation are necessary to improve healthcare infrastructure in developing countries.

Material issues Sumitomo Dainippon Pharma has set targets and KPIs, and we have provided a list of them on pages 25–26.

Patient support and advocacy **Material issues**

Improving disease-related literacy for patients, their families, and society

Holding public lectures

Sumitomo Dainippon Pharma holds public lectures all over Japan not only for patients and their families, but also for the broader general public to promote an accurate understanding of diseases and contribute to solving social issues.

In fiscal 2020, we held seven public lectures on Parkinson’s disease, two on diabetes, and one on dementia with Lewy bodies.

Starting in fiscal 2021, we will conduct questionnaires on the level of understanding and satisfaction with the lectures, which will be reflected in the content.

Working with patient advocacy groups (including donations)

In the spirit of our global slogan “Innovation today, healthier tomorrows,” Sumitomo Dainippon Pharma promotes patient advocacy activities in the hope that all patients and their families can lead healthier and more fulfilling lives.

Main donations in fiscal 2020


Patient advocacy

- Japan Patients Association
- Japan Fabry Disease Patients and Family Association
- Japan Epilepsy Association
- Japan Parkinson’s Disease Association
- Children’s Cancer Association of Japan

Advancing patient advocacy in the U.S.

Sunovion Pharmaceuticals Inc., our U.S. subsidiary, joined the global community in recognizing Parkinson’s Disease Awareness Month with the goal of raising awareness and promoting education about Parkinson’s Disease (PD) in April.

Employees were encouraged to celebrate World



Parkinson’s Day on April 11 and wear a red shirt representing the Parkinson’s tulip symbol or a silver shirt symbolizing the Parkinson’s ribbon. In addition, they

The symbol for Parkinson’s Disease Awareness Month in April

participated in the Parkinson’s Foundation National Moving Day USA Virtual Event and the annual Parkinson’s Unity Walk (the largest single-day grassroots fundraiser for PD research) on April 24.

Raising disease awareness and providing information through websites and SNS

We work with patient groups to create and publish websites aimed at providing information for patients and their families and raising disease awareness among the general public. In fiscal 2020, we also set up official accounts on YouTube and Facebook to diversify and enhance our channels for dissemination of information.

The purpose of *Kokoro Share* content is contributing to better treatment and lifestyle by providing accurate and easy-to-understand information on schizophrenia and bipolar disorder for patients and their families.

The content of *Rehabili Kitchen for Parkinson’s Disease Patients* on our Parkinson’s Disease Station features cooking-themed rehabilitation that can be done at home. The concept of the video is rehabilitation using cooking to increase awareness of each individual movement.



Kokoro Share (Only available in Japanese) <https://kokoro-share.jp/>



Rehabili Kitchen for Parkinson’s Disease Patients (Only available in Japanese) <https://healthcare.ds-pharma.jp/disease/parkinson/kitchen/index.html>

Contribution to Societies

KPIs

- **Activities from patient perspective through healthcare professionals**

We will further promote activities from the patient perspective in the provision of information to healthcare professionals by MRs, in addition to our social contribution activities.

- **Level of understanding and satisfaction of participants in public lectures**

The level of understanding and satisfaction of participants will be used as an indicator to measure how much we are contributing to raising awareness of diseases and solving social issues in the opportunities we have for contact with patients and the general public.

- **Number of support activities through donations and cooperation with patients' associations**

We will support the activities of patient groups to increase literacy about diseases.

- **Dissemination to raise awareness of diseases through our website**

The volume of contents that strengthens the raising of awareness about diseases and the provision of information will be used as an indicator as the dissemination of better information to patients and the general public is important for increasing literacy.

Local community contribution

Material issues

Fulfilling responsibilities and contributing as a member of the community with awareness of harmony with society

Providing learning opportunities leveraging our strengths as a pharmaceutical company

Since fiscal 2012, we have been providing visiting lectures at junior high and high schools. As medical technology continues to progress, we believe that bioethics is important in junior high and high school education as a discipline that does not offer simple right or wrong answers.

Using an original program on bioethics and incorporating the particular perspective that a biology-related corporation can offer, Sumitomo Dainippon Pharma employees deliver visiting lectures. As a program that fosters young learners' abilities to think, feel, and empathize, the program has been highly praised by the Ministry of Economy, Trade and Industry and by classroom teachers.

In fiscal 2020, we updated the content to create a new program for senior high school students on the topic of genome analysis. We ran the new program at four

schools, and approximately 200 students participated. Through this program, we hope that students will recognize the various and diverse ideas of other people, leading to a deeper understanding of themselves and others. Starting in fiscal 2021, we will not only conduct the lectures, but will also carry surveys on understanding and satisfaction to help us improve the program.

We also participated in the fiscal 2020 SDGs Quest Mirai Koshien* in the Kansai area as a special co-sponsor following our involvement in the fiscal 2019 event based on our desire to support new ideas of high school students for solving social issues.

We believe that these initiatives will not only stimulate teen's interest and involvement in science and improve the quality of education in the local community, but will also increase trust in the Company and attract talented human resources in the future.

* SDGs Quest Mirai Koshien: a future-oriented contest in which high school students present SDGs Action ideas that are solutions for a variety of global and social problems, including climate change, energy, biodiversity, gender, water, and more.



"Encouraging Young People to be Repeat Blood Donors," the topic that Kyoto Prefectural Toba High School came up with was selected for the Sumitomo Dainippon Pharma Award.

Publishing the SUKOYAKA Compass website

Since fiscal 2012, Sumitomo Dainippon Pharma has published SUKOYAKA Compass as a part of our website aimed at the children who will be forging the future and their families. Through SUKOYAKA Compass, children learn about the importance of understanding and using medicines correctly, and we also hope that they develop an interest in medicine and that it helps with education about medicines.

Through SUKOYAKA Compass, we publish diverse content, including "Kusuri-no-i-ro-ha," which introduces information such as the action of medicines and the process for the creation of medicines, "O-kusuri Q&A," which explains things like how to use medicines in a Q&A format, "Kusuri no Jiyu Kenkyu Guide," which provides a guide to methods of independent research on medicines and ways of organizing research, "Kusuri no Shigoto Zukan," which introduces work at a pharmaceutical company and the work of a pharmacist, and "Kusuri no Chosen," which introduces the cutting-edge research at

Material issues Sumitomo Dainippon Pharma has set targets and KPIs, and we have provided a list of them on pages 25–26.

Sumitomo Dainippon Pharma, and “Gekkan Karada Column,” which takes up such themes as maintaining and improving the health of junior high school students and ways of dealing with physical ailments. In October 2020, we added “Mirai Tsukuro: SDGs Unit” to show the relationship between health and the SDGs and to introduce the activities of this generation and the Company’s initiatives related to each of the SDG goals.



SUKOYAKA Compass (Only available in Japanese)
<https://www.ds-pharma.co.jp/sukoyaka/>



Scoppi, the navigator on SUKOYAKA Compass

Social contributions and donations

We donate to organizations involved in global health and fostering the next generation, areas we place importance on, by matching donations from officers and employees with corporate donations. In fiscal 2020, we donated to 30 organizations, including four organizations which received these matching donations.

We also participated in READYFOR (crowdfunding) related to COVID-19.

Donation, support, and social contribution activities
https://www.ds-pharma.com/csr/social_contribution/social_contribution.html

Cooperating in vaccination support work by pharmacist volunteers

Since June 2021, we have been cooperating in vaccination support work carried out by the Osaka Pharmaceutical Association for COVID-19 vaccinations at the Osaka mass vaccination center. Employees who are qualified pharmacists and agree to cooperate in support work at vaccination sites can participate in this activity using the Company’s volunteer leave system.

Building even stronger community contribution activities in North America

Since 2012, Sunovion’s “Hands On!” community service

program has engaged employees in volunteer activities that contribute to building stronger communities where they live and work. To date, employees have volunteered more than 32,000 total hours to projects supporting youth and educational programs, health and medical services and community relief initiatives.

During Hands On! 2020, employees pledged to volunteer up to a total of eight hours of service and were allowed to include family members to join in giving back while following COVID-19 safety protocols. As part of their volunteer efforts, employees and family members donated food, clothing and books at locations near their homes, wrote and sent letters to military service members and virtually mentored college students to help them navigate the professional world.



Volunteer activities

KPIs

- **Number of activities to support the development of the next generation and level of understanding and satisfaction of participants**

The level of understanding and satisfaction of participants (students and teachers) will be used as an indicator to measure the contribution of visiting lectures on the topics of bioethics and genome analysis.

- **Number of donations for social contribution that lead to resolution of social issues (disasters, people with disabilities, the environment, biodiversity, etc.)**

We will contribute to solving social issues by supporting organizations involved in global health and education of the next generation, areas the Company places importance on.

- **Number of charitable activities in local communities**

The level of implementation of employee participation-based activities and the number of participants will be used as indicators as it is important for employees to participate and to expand the circle of support.